Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Odetiglucan,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : HiberCell
Deal Size : Undisclosed
Deal Type : Acquisition
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
Details : Imprime PGG is a novel innate immune activator that binds to the dectin-1 receptor and activates innate immunity. HiberCell will integrate Biothera's Minnesota-based staff, operations and other assets into the company.
Product Name : Imprime PGG
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 07, 2020
Lead Product(s) : Odetiglucan,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : HiberCell
Deal Size : Undisclosed
Deal Type : Acquisition